These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19696517)

  • 1. List of drugs in development for neurodegenerative diseases: update June 2009.
    Pogacić Kramp V; Herrling P
    Neurodegener Dis; 2009; 6(4):165-212. PubMed ID: 19696517
    [No Abstract]   [Full Text] [Related]  

  • 2. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 3. List of drugs in development for neurodegenerative diseases: update October 2011.
    Pogačić Kramp V
    Neurodegener Dis; 2012; 9(4):210-83. PubMed ID: 22222285
    [No Abstract]   [Full Text] [Related]  

  • 4. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO; Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract]   [Full Text] [Related]  

  • 5. List of drugs in development for neurodegenerative diseases. Update June 2008.
    Pogacić V; Herrling P
    Neurodegener Dis; 2009; 6(1-2):37-86. PubMed ID: 18679022
    [No Abstract]   [Full Text] [Related]  

  • 6. List of drugs in development for neurodegenerative diseases: update June 2010.
    Pogačić Kramp V; Herrling P
    Neurodegener Dis; 2011; 8(1-2):44-94. PubMed ID: 20689264
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract]   [Full Text] [Related]  

  • 8. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 9. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 10. List of drugs in development for neurodegenerative diseases. Update March 2005.
    Valentine L; Kwon MO; Herrling P
    Neurodegener Dis; 2004; 1(6):269-322. PubMed ID: 16908978
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug Development for Neurodegenerative Diseases--Second Annual marcus evans Conference. Advances in drug development for NDD and expediting discovery through novel compounds and sound clinical trials.
    Morimoto B
    IDrugs; 2010 Jul; 13(7):440-3. PubMed ID: 20582866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A need for speed: Signals in drug development.
    Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053
    [No Abstract]   [Full Text] [Related]  

  • 13. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

  • 14. List of drugs in development for neurodegenerative diseases.
    Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(1):50-70. PubMed ID: 16908974
    [No Abstract]   [Full Text] [Related]  

  • 15. Foreword: neurodegenerative diseases: challenges and opportunities.
    Cuny GD
    Future Med Chem; 2012 Sep; 4(13):1647-9. PubMed ID: 22924500
    [No Abstract]   [Full Text] [Related]  

  • 16. QT as a safety biomarker in drug development.
    Whellan DJ; Green CL; Piccini JP; Krucoff MW
    Clin Pharmacol Ther; 2009 Jul; 86(1):101-4. PubMed ID: 19474784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough programme turns two.
    Mullard A
    Nat Rev Drug Discov; 2014 Dec; 13(12):873-5. PubMed ID: 25435204
    [No Abstract]   [Full Text] [Related]  

  • 18. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Neurodegenerative Disorders: Synthesis, Drug Delivery Strategies and Biological Evaluation of New Therapeutic Agents.
    Di Stefano A; Reale M
    Cent Nerv Syst Agents Med Chem; 2017; 17(2):89. PubMed ID: 28820058
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges and opportunities in neuroscience research.
    Coleman PJ; Barrow JC
    ChemMedChem; 2012 Mar; 7(3):339-41. PubMed ID: 22383223
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.